Top

Published in:

01-01-2013 | Short communication

Role of ¹⁸F-fluoride PET/CT in the assessment of multiple myeloma: initial experience

Authors: Yuji Nishiyama, Ukihide Tateishi, Kazuya Shizukuishi, Ayako Shishikura, Etsuko Yamazaki, Hiroto Shibata, Tomohiro Yoneyama, Yoshiaki Ishigatsubo, Tomio Inoue

Published in: Annals of Nuclear Medicine | Issue 1/2013

Abstract

Purpose

The aim of this study was to report our early experience with ¹⁸F-fluoride PET/CT for detecting lesions and evaluate the usefulness of this modality in the assessment of multiple myeloma (MM).

Materials and methods

¹⁸F-fluoride PET/CT and ^99mTc-MDP bone scintigraphy (BS) studies from 7 myeloma patients (4 male and 3 female, mean age 55 years) diagnosed according to standard criteria were reviewed retrospectively. Two reviewers visually and quantitatively analyzed the images and recorded their findings after reaching a consensus. Diagnostic certainty regarding the presence or absence of myeloma lesions was evaluated according to the reference standard consisting of whole-body magnetic resonance imaging and whole-body X-ray.

Results

A total of 93 affected areas were definite according to the reference standard. Of these, 83 affected areas (89 %) were identified on ¹⁸F-fluoride PET/CT, whereas 54 affected areas (58 %) were found on BS. Mean SUVmax in the affected areas was 9.8 ± 3.2 (standard deviation) ranging from 5.0 to 21.2. A total of s17 lesions with bone fracture were also detected by ¹⁸F-fluoride PET/CT and 2 lesions (12 %) were negative on BS.

Conclusion

Our result showed that ¹⁸F-fluoride PET was a possible modality to detect areas of lesions in patients with MM.

Durie BG, Waxman AD, D’Agnolo A, Williams CM. Whole-body 18F-FDG PET identifies high-risk myeloma. J Nucl Med. 2002;43:1457–63.PubMed

Smith A, Wisloff F, Samson D, Myeloma Forum UK, Nordic Myeloma Study Group. British Committee for Standards in Haematology: guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol. 2006;132:410–51.PubMedCrossRef

Durie BG. The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system. Eur J Cancer. 2006;42:1539–43.PubMedCrossRef

D’Sa S, Abildgaard N, Tighe J, Shaw P, Hall-Craggs M. Guidelines for the use of imaging in the management of myeloma. Br J Haematol. 2007;137:49–63.PubMed

Zamagni E, Nanni C, Patriarca F, Englaro E, Castellucci P, Geatti O, et al. A prospective comparison of 18F fluorodeoxyglucose positron emission tomography–computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica. 2007;92:50–5.PubMedCrossRef

Nanni C, Zamagni E, Farsad M, Castellucci P, Tosi P, Cangini D, et al. Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. Eur J Nucl Med Mol Imaging. 2006;33:525–31.PubMedCrossRef

Ludwig H, Kupman W, Sinzinger H. Radiography and bone scintigraphy in multiple myeloma: a comparative analysis. Br J Radiol. 1982;55:173–81.PubMedCrossRef

Bataille R, Chevalier J, Rossi M, et al. Bone scintigraphy in plasma cell myeloma. A prospective study of 70 patients. Radiology. 1982;145:801–4.PubMed

Breyer RJ 3rd, Mulligan ME, Smith SE, et al. Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma. Skeletal Radiol. 2006;35:632–40.PubMedCrossRef

10.

Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A, et al. Prognostic relevance of 18F-FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118:5989–95.PubMedCrossRef

11.

Grant FD, Fahey FH, Packard AB, Davis RT, Alavi A, Treves ST. Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J Nucl Med. 2008;49:68–78.PubMedCrossRef

12.

Hawkins RA, Choi Y, Huang SC, Hoh CK, Dahlbom M, Schiepers C, et al. Evaluation of skeletal kinetics of fluorine 18-fluoride ion and PET. J Nucl Med. 1992;33:633–42.PubMed

13.

Even-Sapir E, Metser U, Flusser G, Zuriel L, Kollender Y, Lerman H, et al. Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med. 2004;45:272–8.PubMed

14.

Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, et al. Myeloma management guidelines: a consensus report from the scientific advisors of the international myeloma foundation. Hematol J. 2003;4:379–98.PubMedCrossRef

15.

Even-Sapir Ammeter U, Mishani E, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: ^99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, ¹⁸F-fluoride PET, and ¹⁸F-fluoride PET/CT. J Nucl Med. 2006;47:287–97.

Title: Role of 18F-fluoride PET/CT in the assessment of multiple myeloma: initial experience
Authors: Yuji Nishiyama
Ukihide Tateishi
Kazuya Shizukuishi
Ayako Shishikura
Etsuko Yamazaki
Hiroto Shibata
Tomohiro Yoneyama
Yoshiaki Ishigatsubo
Tomio Inoue
Publication date: 01-01-2013
Publisher: Springer Japan
Published in: Annals of Nuclear Medicine / Issue 1/2013
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-012-0647-7

At a glance: The STEP trials

Springer Medicine

Role of ¹⁸F-fluoride PET/CT in the assessment of multiple myeloma: initial experience

Abstract

Purpose

Materials and methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2013

A novel PET scanner with semiconductor detectors may improve diagnostic accuracy in the metastatic survey of head and neck cancer patients

Significant impact of transient deterioration of renal function on dosimetry in PRRT

A heuristic statistical stopping rule for iterative reconstruction in emission tomography

The current status of an FDG-PET cancer screening program in Japan, based on a 4-year (2006–2009) nationwide survey

Predictive value of 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography/computed tomography for outcome of carbon ion radiotherapy in patients with head and neck mucosal malignant melanoma

Dynamic sequence respiratory gated perfusion pulmonary SPECT without external tracking device